Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) Director Schutter Richard Urbain De purchased 4,900 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average price of C$14.35 per share, with a total value of C$70,315.00.

Shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) traded down 4.45% during midday trading on Friday, reaching $17.62. 1,440,357 shares of the company’s stock traded hands. The firm’s market cap is $6.14 billion. The stock has a 50-day moving average price of $20.01 and a 200 day moving average price of $17.58. Valeant Pharmaceuticals Intl Inc has a 12 month low of $11.20 and a 12 month high of $40.68.

ILLEGAL ACTIVITY NOTICE: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/08/26/schutter-richard-urbain-de-acquires-4900-shares-of-valeant-pharmaceuticals-intl-inc-vrx-stock.html.

VRX has been the subject of a number of research analyst reports. Scotiabank lifted their price target on Valeant Pharmaceuticals Intl to C$19.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 10th. Royal Bank Of Canada reiterated a “sector perform” rating and set a C$26.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Friday, June 9th. TD Securities reduced their price target on Valeant Pharmaceuticals Intl to C$20.50 and set a “hold” rating for the company in a report on Wednesday, May 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a report on Thursday, June 29th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Valeant Pharmaceuticals Intl currently has an average rating of “Hold” and a consensus price target of C$23.33.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex.

Receive News & Stock Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related stocks with our FREE daily email newsletter.